Abstract
Neuropeptides are found throughout the entire nervous system where they can act as neurotransmitter, neuromodulator or neurohormone. In those functions, they play important roles in the regulation of cognition and behavior. In brain disorders like Alzheimer’s disease (AD), where abnormal cognition and behavior are observed, the study of neuropeptides is particularly interesting since altered neuropeptides can function as biomarkers or as targets for new medication. In this article neuropeptides with relevance to AD are listed and their influence on cognitive and behavioral disturbances is discussed. Findings from human cerebrospinal fluid and brain tissue, and AD mouse models are described and related to the pathophysiology and symptomatology of the disease. In the past, clinical trials with neuropeptides have often failed due to insufficient delivery to the brain. Therefore, new strategies to target the brain with peptide drugs are also covered.
Keywords: Behavior, blood-brain barrier, clinical trial, cognition, drug delivery systems, pathophysiology, therapy.
Current Alzheimer Research
Title:Neuropeptides in Alzheimer’s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities
Volume: 10 Issue: 5
Author(s): Debby Van Dam, Annemie Van Dijck, Leen Janssen and Peter Paul De Deyn
Affiliation:
Keywords: Behavior, blood-brain barrier, clinical trial, cognition, drug delivery systems, pathophysiology, therapy.
Abstract: Neuropeptides are found throughout the entire nervous system where they can act as neurotransmitter, neuromodulator or neurohormone. In those functions, they play important roles in the regulation of cognition and behavior. In brain disorders like Alzheimer’s disease (AD), where abnormal cognition and behavior are observed, the study of neuropeptides is particularly interesting since altered neuropeptides can function as biomarkers or as targets for new medication. In this article neuropeptides with relevance to AD are listed and their influence on cognitive and behavioral disturbances is discussed. Findings from human cerebrospinal fluid and brain tissue, and AD mouse models are described and related to the pathophysiology and symptomatology of the disease. In the past, clinical trials with neuropeptides have often failed due to insufficient delivery to the brain. Therefore, new strategies to target the brain with peptide drugs are also covered.
Export Options
About this article
Cite this article as:
Dam Debby Van, Dijck Annemie Van, Janssen Leen and Deyn Peter Paul De, Neuropeptides in Alzheimer’s Disease: From Pathophysiological Mechanisms to Therapeutic Opportunities, Current Alzheimer Research 2013; 10 (5) . https://dx.doi.org/10.2174/1567205011310050001
DOI https://dx.doi.org/10.2174/1567205011310050001 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents on Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Capillary Electrophoresis with Mass Spectrometry: Applications to Metabolomic Analysis
Current Metabolomics The Enigmatic Drug Binding Site for Sodium Channel Inhibitors
Current Molecular Pharmacology Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling
Current Neuropharmacology When “Chems” Meet Sex: A Rising Phenomenon Called “ChemSex”
Current Neuropharmacology Impact of Ritonavir, Atazanavir and Their Combination on the CYP3A4 Induction by Efavirenz in Primary Human Hepatocytes
Drug Metabolism Letters From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Conceptualizing Excessive Behaviour Syndromes: A Systematic Review
Current Psychiatry Reviews Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide
Protein & Peptide Letters Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Attitudinal & Knowledge Barriers Towards Effective Pain Assessment & Management in Dementia: A Narrative Synthesis
Current Alzheimer Research Raphe-Hippocampal Serotonin Neurotransmission In The Sex Related Differences of Adaptation to Stress: Focus on Serotonin-1A Receptor
Current Neuropharmacology Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Bioanalytical and Biophysical Techniques for the Elucidation of the Mode of Action of Metal-Based Drugs
Current Topics in Medicinal Chemistry Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Association of Amyloid Burden, Brain Atrophy and Memory Deficits in Aged Apolipoprotein ε4 Mice
Current Alzheimer Research Phyto-derived Products as Matrix Metalloproteinases Inhibitors in Cardiovascular Diseases
Current Hypertension Reviews Microglial Cathepsin B and <i>Porphyromonas gingivalis</i> Gingipains as Potential Therapeutic Targets for Sporadic Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets